{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:10:14Z","timestamp":1790021414979,"version":"4.0.1"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific & Industrial Research","doi-asserted-by":"publisher","award":["37WS(0090)\/2023-24\/EMR-II\/ASPIRE"],"award-info":[{"award-number":["37WS(0090)\/2023-24\/EMR-II\/ASPIRE"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/SG\/9\/2024-01073"],"award-info":[{"award-number":["EMDR\/SG\/9\/2024-01073"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/SG\/11\/2024-00-01002"],"award-info":[{"award-number":["EMDR\/SG\/11\/2024-00-01002"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["EMDR\/SG\/12\/2023-2719"],"award-info":[{"award-number":["EMDR\/SG\/12\/2023-2719"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.actbio.2026.09.035","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:44:19Z","timestamp":1789944259000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leukemic Stem Cell\u2013Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein\u2013Driven Acute Myeloid Leukemia by Silencing B-Cell Lymphoma 2"],"prefix":"10.1016","author":[{"given":"Mohd","family":"Ayoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devangi","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas Kumar","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liku","family":"Biswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surajit","family":"Karmakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7894-8297","authenticated-orcid":false,"given":"Subhasree Roy","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2026.09.035_bib0001","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/leu.2014.107","article-title":"Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia","volume":"28","author":"Walter","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.actbio.2026.09.035_bib0002","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.7150\/jca.32326","article-title":"The Epidemiological Trend of Acute Myeloid Leukemia in Childhood: a Population-Based Analysis","volume":"10","author":"Chen","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.actbio.2026.09.035_bib0003","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood-2003-03-0836","article-title":"Impaired selectin-ligand biosynthesis and reduced inflammatory responses in \u03b2-1,4-galactosyltransferase-I\u2013deficient mice","volume":"102","author":"Asano","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2026.09.035_bib0004","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1093\/emboj\/18.13.3564","article-title":"The Mll\u2013AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis","volume":"18","author":"Dobson","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/j.actbio.2026.09.035_bib0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1947601911408076","article-title":"Genetic abnormalities and challenges in the treatment of acute myeloid leukemia","volume":"2","author":"Kumar","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.actbio.2026.09.035_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-025-59930-9","article-title":"Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12","volume":"16","author":"Troester","year":"2025","journal-title":"Nature Communications"},{"key":"10.1016\/j.actbio.2026.09.035_bib0007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccr.2006.08.020","article-title":"Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia","volume":"10","author":"Somervaille","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.actbio.2026.09.035_bib0008","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/leu.2012.232","article-title":"Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"27","author":"Greenberg","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.actbio.2026.09.035_bib0009","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2026.09.035_bib0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.canlet.2012.03.005","article-title":"Targeting survivin in cancer","volume":"332","author":"Altieri","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.actbio.2026.09.035_bib0011","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/j.1460-2075.1996.tb00610.x","article-title":"The relationship between sequence-specific termination of DNA replication and transcription","volume":"15","author":"Mohanty","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.actbio.2026.09.035_bib0012","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrc2439","article-title":"MYB function in normal and cancer cells","volume":"8","author":"Ramsay","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2026.09.035_bib0013","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI82978","article-title":"MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C","volume":"126","author":"Zhu","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.actbio.2026.09.035_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark. Res."},{"key":"10.1016\/j.actbio.2026.09.035_bib0015","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.actbio.2026.09.035_bib0016","article-title":"CD123 Targeted Epigenetic Nanotherapy for Fusion Oncoprotein MLL-AF9 Rearranged Acute Myeloid Leukemia in Preclinical and Patient Derived Xenograft Models","author":"Kushwaha","year":"2025","journal-title":"Adv. Healthc. Mater"},{"key":"10.1016\/j.actbio.2026.09.035_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044197","article-title":"Effective Non-Viral Delivery of siRNA to Acute Myeloid Leukemia Cells with Lipid-Substituted Polyethylenimines","volume":"7","author":"Landry","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.actbio.2026.09.035_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123516","article-title":"Bone marrow microenvironment-responsive polymeric-drug\/siRNA regulates leukemia stem cells assisting for prevention of AML relapse","volume":"324","author":"Cheng","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2026.09.035_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044197","article-title":"Effective Non-Viral Delivery of siRNA to Acute Myeloid Leukemia Cells with Lipid-Substituted Polyethylenimines","volume":"7","author":"Landry","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.actbio.2026.09.035_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.32","article-title":"Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy","volume":"3","author":"Sun","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.actbio.2026.09.035_bib0021","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/10717544.2017.1367976","article-title":"Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics","volume":"24","author":"Wu","year":"2017","journal-title":"Drug Deliv"},{"key":"10.1016\/j.actbio.2026.09.035_bib0022","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jconrel.2006.02.009","article-title":"A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes","volume":"112","author":"Werth","year":"2006","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.actbio.2026.09.035_bib0023","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1016\/j.actbio.2014.02.037","article-title":"Storage stability of optimal liposome\u2013polyethylenimine complexes (lipopolyplexes) for DNA or siRNA delivery","volume":"10","author":"Ewe","year":"2014","journal-title":"Acta Biomater"},{"key":"10.1016\/j.actbio.2026.09.035_bib0024","doi-asserted-by":"crossref","first-page":"25633","DOI":"10.1021\/acsami.0c06186","article-title":"Epigenetic Regulation of Bmi1 by Ubiquitination and Proteasomal Degradation Inhibit Bcl-2 in Acute Myeloid Leukemia","volume":"12","author":"Kushwaha","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2026.09.035_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1616","article-title":"Synthetic quorum-sensing circuit to control consortial biofilm formation and dispersal in a microfluidic device","volume":"3","author":"Hong","year":"2012","journal-title":"Nature Communications"},{"key":"10.1016\/j.actbio.2026.09.035_bib0026","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1021\/nn400334y","article-title":"Single-step assembly of DOX\/ICG loaded lipid\u2013polymer nanoparticles for highly effective chemo-photothermal combination therapy","volume":"7","author":"Zheng","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.09.035_bib0027","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1021\/bi500021j","article-title":"Interactions of Indocyanine Green and Lipid in Enhancing Near-Infrared Fluorescence Properties: The Basis for Near-Infrared Imaging in Vivo","volume":"53","author":"Kraft","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.actbio.2026.09.035_bib0028","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3324\/haematol.2019.243360","article-title":"P2\u00d77 promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of Pbx3","volume":"106","author":"Feng","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.actbio.2026.09.035_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.actbio.2026.09.035_bib0030","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/21691401.2018.1434533","article-title":"Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy","volume":"46","author":"Haghiralsadat","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.actbio.2026.09.035_bib0031","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ymthe.2019.05.002","article-title":"Lipidoid-siRNA Nanoparticle-Mediated IL-1\u03b2 Gene Silencing for Systemic Arthritis Therapy in a Mouse Model","volume":"27","author":"Song","year":"2019","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.actbio.2026.09.035_bib0032","article-title":"Fabrication of aptamer-guided siRNA loaded lipopolyplexes for gene silencing of notch 1 in MDA-mb-231 triple negative breast cancer cell line","volume":"65","author":"Gharaibeh","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.actbio.2026.09.035_bib0033","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1021\/nn301975s","article-title":"Identification and Characterization of Receptor-Specific Peptides for siRNA Delivery","volume":"6","author":"Ren","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.09.035_bib0034","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"Journal of Hematology & Oncology 2020"},{"issue":"12","key":"10.1016\/j.actbio.2026.09.035_bib0035","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"11","author":"Kanasty","year":"2013","journal-title":"Nature Materials"},{"key":"10.1016\/j.actbio.2026.09.035_bib0036","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/polym11091515","article-title":"Aptamer-Functionalized Liposomes as a Potential Treatment for Basal Cell Carcinoma","volume":"11","author":"Cadinoiu","year":"2019","journal-title":"Polymers"},{"key":"10.1016\/j.actbio.2026.09.035_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02618-6","article-title":"Peptidomimetic blockade of MYB in acute myeloid leukemia","author":"Ramaswamy","year":"2018","journal-title":"Nature Communications"},{"issue":"39","key":"10.1016\/j.actbio.2026.09.035_bib0038","first-page":"1277","article-title":"Immune checkpoints regulate acute myeloid leukemia stem cells","volume":"6","author":"Reinhardt","year":"2025","journal-title":"Leukemia 2025 39"},{"key":"10.1016\/j.actbio.2026.09.035_bib0039","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1021\/nn202772p","article-title":"siRNA-Aptamer Chimeras on Nanoparticles, Preserving Targeting Functionality for Effective Gene Silencing","volume":"5","author":"Bagalkot","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.09.035_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1416737","article-title":"Dual conjugation of magnetic nanoparticles with antibodies and siRNA for cell-specific gene silencing in vascular cells","volume":"4","author":"Karpinska","year":"2024","journal-title":"Frontiers in Drug Delivery"},{"key":"10.1016\/j.actbio.2026.09.035_bib0041","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2018.09.62","article-title":"Transcription regulation of MYB: a potential and novel therapeutic target in cancer","volume":"6","author":"Mitra","year":"2018","journal-title":"Ann. Transl. Med."},{"issue":"31","key":"10.1016\/j.actbio.2026.09.035_bib0042","first-page":"638","article-title":"Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"7","author":"Gilleron","year":"2013","journal-title":"Nature Biotechnology 2013 31"},{"key":"10.1016\/j.actbio.2026.09.035_bib0043","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jconrel.2011.10.009","article-title":"Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design","volume":"158","author":"Buyens","year":"2012","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.actbio.2026.09.035_bib0044","doi-asserted-by":"crossref","first-page":"9739","DOI":"10.1073\/pnas.1409431111","article-title":"Probing the inherent stability of siRNA immobilized on nanoparticle constructs","volume":"111","author":"Barnaby","year":"2014","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.actbio.2026.09.035_bib0045","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3390\/ph18060864","article-title":"Engineering Lipid\u2013Polymer Nanoparticles for siRNA Delivery to Cancer Cells","volume":"18","author":"Manda","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.actbio.2026.09.035_bib0046","doi-asserted-by":"crossref","first-page":"10430","DOI":"10.1021\/jacs.4c18308","article-title":"Lipid-siRNA Organization Modulates the Intracellular Dynamics of Lipid Nanoparticles","volume":"147","author":"Mo","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2026.09.035_bib0047","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"issue":"13","key":"10.1016\/j.actbio.2026.09.035_bib0048","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"1","author":"Xu","year":"2020","journal-title":"Journal of Hematology & Oncology 2020 13"},{"key":"10.1016\/j.actbio.2026.09.035_bib0049","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijpharm.2008.09.039","article-title":"Polymeric Nanoparticles for siRNA Delivery and Gene Silencing","volume":"367","author":"Patil","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2026.09.035_bib0050","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/sciadv.aax0801","article-title":"Covalently tethering siRNA to hydrogels for localized, controlled release and gene silencing","volume":"5","author":"Nguyen","year":"2019","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.actbio.2026.09.035_bib0051","article-title":"miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia","volume":"1","author":"Jiang","year":"2016","journal-title":"Nature Communications 2016 7"},{"key":"10.1016\/j.actbio.2026.09.035_bib0052","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.actbio.2026.09.035_bib0053","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2301067120","article-title":"Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm","volume":"120","author":"Zheng","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.actbio.2026.09.035_bib0054","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.omtn.2018.08.023","article-title":"Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies","volume":"13","author":"Yang","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.actbio.2026.09.035_bib0055","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/10717544.2017.1367976","article-title":"Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics","volume":"24","author":"Wu","year":"2017","journal-title":"Drug Deliv"},{"key":"10.1016\/j.actbio.2026.09.035_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102225","article-title":"Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells","volume":"14","author":"Camorani","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2026.09.035_bib0057","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.actbio.2026.09.035_bib0058","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.actbio.2026.09.035_bib0059","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3390\/pharmaceutics13101681","article-title":"Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for t(8;21) pediatric acute myeloid leukemia","volume":"13","author":"Connerty","year":"2021","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.actbio.2026.09.035_bib0060","article-title":"Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines","volume":"1","author":"Nakamura","year":"2016","journal-title":"Scientific Reports 2016 6"},{"key":"10.1016\/j.actbio.2026.09.035_bib0061","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00277-019-03713-y","article-title":"Lipid nanoparticle mediated siRNA delivery for safe targeting of human CML in vivo","volume":"98","author":"Jyotsana","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.actbio.2026.09.035_bib0062","article-title":"Reshaping tumor immune microenvironment through ROS-responsive prodrug polyplexes via synergistic effect of CRISPRi system and epigenetic inhibitor for breast cancer therapy","volume":"35","author":"Deng","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.actbio.2026.09.035_bib0063","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1021\/acs.biomac.5c00954","article-title":"Construction of ROS-Responsive Poly(\u03b2-amino ester)-poly(\u03b2-thioether ester) Copolymer for Enhancing Gene Delivery and Gene Therapy","volume":"26","author":"Li","year":"2025","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2026.09.035_bib0064","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2012-02-413187","article-title":"Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes","volume":"123","author":"Pattabiraman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2026.09.035_bib0065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41590-018-0311-z","article-title":"The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity","volume":"20","author":"Gautam","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.actbio.2026.09.035_bib0066","doi-asserted-by":"crossref","first-page":"34191","DOI":"10.18632\/oncotarget.5763","article-title":"Overexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide","volume":"6","author":"Kang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.actbio.2026.09.035_bib0067","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.3324\/haematol.2015.131508","article-title":"Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"100","author":"Stevens","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.actbio.2026.09.035_bib0068","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/bloodadvances.2017007856","article-title":"Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance","volume":"1","author":"Stevens","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.actbio.2026.09.035_bib0069","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5763","article-title":"Overexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide","volume":"6","author":"Kang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.actbio.2026.09.035_bib0070","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature04980","article-title":"Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9","volume":"442","author":"Krivtsov","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2026.09.035_bib0071","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccr.2006.08.020","article-title":"Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia","volume":"10","author":"Somervaille","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.actbio.2026.09.035_bib0072","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2014.72","article-title":"Acute Myeloid Leukemia Cells Harboring MLL Fusion Genes or with the Acute Promyelocytic Leukemia Phenotype Are Sensitive to the Bcl-2-selective Inhibitor ABT-199","volume":"28","author":"Niu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.actbio.2026.09.035_bib0073","doi-asserted-by":"crossref","first-page":"874","DOI":"10.4161\/onci.20636","article-title":"Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk","volume":"1","author":"Chinnery","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.actbio.2026.09.035_bib0074","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.4049\/jimmunol.1500262","article-title":"Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion","volume":"195","author":"Khaznadar","year":"2015","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.actbio.2026.09.035_bib0075","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2012-02-413187","article-title":"Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes","volume":"123","author":"Pattabiraman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2026.09.035_bib0076","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.actbio.2026.09.035_bib0077","article-title":"Aggressive leukemia driven by MLL-AF9","volume":"5","author":"Stavropoulou","year":"2017","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.actbio.2026.09.035_bib0078","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI82978","article-title":"MLL-AF9\u2013 and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C","volume":"126","author":"Zhu","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.actbio.2026.09.035_bib0079","article-title":"Inhibition of c-Myc Overcomes Cytotoxic Drug Resistance in Acute Myeloid Leukemia Cells by Promoting Differentiation","volume":"9","author":"Pan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.actbio.2026.09.035_bib0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3324\/haematol.2020.262121","article-title":"Differentiation therapy of myeloid leukemia: four decades of development","volume":"106","author":"Madan","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.actbio.2026.09.035_bib0081","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1038\/s41467-021-26849-w","article-title":"Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy","volume":"12","author":"Ngo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2026.09.035_bib0082","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2026.09.035_bib0083","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1112059","article-title":"NK cell defects: implication in acute myeloid leukemia","volume":"14","author":"D\u2019Silva","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2026.09.035_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100709","article-title":"Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1\/PD-L1 and CTLA-4 pathways","volume":"45","author":"Bewersdorf","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.actbio.2026.09.035_bib0085","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/cells11142249","article-title":"Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"11","author":"Abaza","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.actbio.2026.09.035_bib0086","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.actbio.2026.09.035_bib0087","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-10251-7","article-title":"In vivo bio-distribution and acute toxicity evaluation of greenly synthesized ultra-small gold nanoparticles with different biological activities","volume":"12","author":"Aljohani","year":"2022","journal-title":"Scientific Reports"},{"key":"10.1016\/j.actbio.2026.09.035_bib0088","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2026.09.035_bib0089","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2018.07.024","article-title":"The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia","volume":"286","author":"Guo","year":"2018","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.actbio.2026.09.035_bib0090","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acs.molpharmaceut.6b01150","article-title":"Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy","volume":"14","author":"Guo","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2026.09.035_bib0091","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.3390\/nano11112974","article-title":"CD123-Targeted Nano-Curcumin Molecule Enhances Cytotoxic Efficacy in Leukemic Stem Cells","volume":"11","author":"Nirachonkul","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.actbio.2026.09.035_bib0092","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell\u2013directed dual-affinity retargeting platform","volume":"127","author":"Al-Hussaini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2026.09.035_bib0093","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0005-2736(91)90246-5","article-title":"Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo","volume":"1066","author":"Allen","year":"1991","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes"},{"key":"10.1016\/j.actbio.2026.09.035_bib0094","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","article-title":"Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes","volume":"268","author":"Klibanov","year":"1990","journal-title":"FEBS Lett"},{"key":"10.1016\/j.actbio.2026.09.035_bib0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor \u03b1 Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.actbio.2026.09.035_bib0096","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706126006367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706126006367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:29:48Z","timestamp":1790018988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706126006367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":96,"alternative-id":["S1742706126006367"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2026.09.035","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leukemic Stem Cell\u2013Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein\u2013Driven Acute Myeloid Leukemia by Silencing B-Cell Lymphoma 2","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2026.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}